RBC Capital raised the firm’s price target on Avid Bioservices to $12 from $8 and keeps an Outperform rating on the shares. The company’s Q1 results missed on revenue and EBITDA, but its bookings were “well ahead of estimates”, with “broad-based” contributions coming from a combination of new customers, early and late-stage work and even a commercial mandate, the analyst tells investors in a research note. The management also said the increased mix of early work this quarter should slightly accelerate the near-term burn rates, which improves visibility on the management’s reaffirmed $160M-168M FY25 revenue guidance, RBC added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDMO:
- Closing Bell Movers: Oracle gains 9% after Q1 earnings beat
- Avid Bioservices Reports Growth and Strong Pipeline
- Avid Bioservices reports Q1 EPS (9c) , consensus (5c)
- Avid Bioservices backs FY25 revenue view160M-$168M, consensus $162.83M
- Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue